Home › Research › Clinical trials
Interim Phase 1 multiple ascending dose results for remternetug (LY3372993) in Alzheimer's disease
Eli Lilly and Company (interim data presented at AD/PD 2023). Presented at AD/PD 2023 Conference (Gothenburg, Sweden); covered by ALZFORUM and NeurologyLive, 2023-04
Topic: Amyloid, tau and blood-test diagnosis
Eli Lilly's newer anti-amyloid antibody remternetug showed fast, dose-dependent removal of amyloid plaques in a small early trial: three-quarters of people getting the higher doses had their brain amyloid drop below the threshold used to call a scan 'positive' within about six months. Brain-swelling side effects (ARIA) occurred in about a quarter of participants, similar to other approved anti-amyloid drugs, with one symptomatic case.
Key findings
- 41 participants total across placebo and 250-2,800 mg dose groups
- 75% (18/24) of participants on the three highest doses cleared amyloid below 24.1 centiloids by day 169
- At the highest dose (2,800 mg), all participants fell below the amyloid-positivity threshold within 3 months
- 10 ARIA-E and 7 ARIA-H cases reported; all ARIA-E occurred in APOE4 carriers, one symptomatic case
- No anti-drug antibodies or systemic infusion reactions detected
Why it matters
Eli Lilly's newer anti-amyloid antibody remternetug showed fast, dose-dependent removal of amyloid plaques in a small early trial: three-quarters of people getting the higher doses had their brain amyloid drop below the threshold used to call a scan 'positive' within about six months. Brain-swelling side effects (ARIA) occurred in about a quarter of participants, similar to other approved anti-amyloid drugs, with one symptomatic case.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Study designRCT
- Participants41
- Effect size18 of 24 participants (75%) on the three highest doses (700-2,800 mg) cleared amyloid to below 24.1 centiloids by day 169, from baselines of 82-96 centiloids; at 2,800 mg, every participant fell below the amyloid-positivity threshold within 3 months
- Evidence strengthEarly
Limitations
This is interim data from a small (n=41), unpublished phase 1 trial presented at a conference, not yet in a peer-reviewed journal; long-term efficacy on cognition/function has not been reported from this analysis. (Phase 1b randomized, placebo-controlled multiple-ascending-dose design.)
How this study scored 16/100
Conference abstract — not peer-reviewed. It scored 42 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for indexed in PubMed because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 28 of the 66 points we could judge it on, which is 42 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Presented at AD/PD 2023 Conference (Gothenburg, Sweden); covered by ALZFORUM and NeurologyLive) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 11 / 12 | A randomised controlled trial |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 3 / 10 | Conference abstract — not peer-reviewed. Journal string identifies this as a conference abstract or presentation. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 41 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 28 / 66 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 28 of the 66 points we could judge it on is 42 out of 100. |
| Total | 42 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. The record's author field reads “Eli Lilly and Company (interim data presented at AD/PD 2023)”, which cannot be turned into a citation name, so it is left out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Interim Phase 1 multiple ascending dose results for remternetug (LY3372993) in Alzheimer's disease. (2023). Presented at AD/PD 2023 Conference (Gothenburg, Sweden); covered by ALZFORUM and NeurologyLive.
Vancouver
Interim Phase 1 multiple ascending dose results for remternetug (LY3372993) in Alzheimer's disease. Presented at AD/PD 2023 Conference (Gothenburg, Sweden); covered by ALZFORUM and NeurologyLive. 2023.
BibTeX
@article{study2023-955fa2a8,
title = {{Interim Phase 1 multiple ascending dose results for remternetug (LY3372993) in Alzheimer's disease}},
journal = {Presented at AD/PD 2023 Conference (Gothenburg, Sweden); covered by ALZFORUM and NeurologyLive},
year = {2023}
}